Oncolys BioPharma Inc. They have developed a groundbreaking treatment called Telomelysin, which is a novel oncolytic virus therapy. This therapy has shown promising results in clinical trials and offers a new approach to fighting various types of cancer.

In addition to Telomelysin, Oncolys also offers a range of other products and therapies. This includes OBP-301, OBP-702, OBP-2011, OBP-601 (Censavudine), OBP-801, and OBP-401. These products target different cancer types and have the potential to revolutionize cancer treatment.

Oncolys is committed to advancing the field of oncology and improving the lives of cancer patients. With a dedicated team of researchers and scientists, they continue to push the boundaries of what is possible in cancer therapy. By combining cutting-edge science with a patient-centered approach, Oncolys is at the forefront of developing innovative and effective cancer treatments